The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1483
ISSUE 1483
December 7, 2015
Issue 1483
- Insulin Degludec (Tresiba) - A New Long-Acting Insulin for Diabetes
- Drugs Past Their Expiration Date
- Deoxycholic Acid (Kybella) for Double Chin
- Ferric Citrate (Auryxia) for Hyperphosphatemia
- Nivolumab (Opdivo) plus Ipilimumab (Yervoy) for Metastatic Melanoma
- Corrections: Eloctate for Hemophilia A & Sumatriptan Patch (Zecuity) for Migraine
Subscribers: Log in to read full issue. Not a subscriber? Subscribe or purchase issue.
Insulin Degludec (Tresiba) - A New Long-Acting Insulin for Diabetes
December 7, 2015 (Issue: 1483)
The FDA has approved insulin degludec (Tresiba –
Novo Nordisk) for treatment of adults with type 1 or
type 2 diabetes. Insulin degludec is the third long-acting
human insulin analog to be approved by the
FDA; insulin detemir (Levemir) and...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.